RxDoctor Payments Data

Ronald Vanderlaan, MD

Cardiovascular Disease · Grand Rapids, MINPI 1447299599

Payments from drug & device makers

$14,624in general payments, 2019–2025

Across 787 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$1K
  • Bayer$1K
  • Merck$1K
  • Pfizer$938
  • Novartis$894
  • plus $8K from 46 others

What the payments were for

  • Food & beverage$14,41199%
  • Education$2131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,624 in reported general payments places this provider in the 70th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$263,064
Medicare patients
476
Services billed
6,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban559$684,283
XareltoRivaroxaban313$364,892
EntrestoSacubitril/Valsartan203$271,709
FarxigaDapagliflozin Propanediol128$143,469
Repatha SureclickEvolocumab192$131,674
CamzyosMavacamten14$111,172
JardianceEmpagliflozin84$95,770
VerquvoVericiguat28$34,058
Metoprolol Succinate1,110$27,822
MultaqDronedarone Hcl14$23,460
BrilintaTicagrelor19$16,364
NexlizetBempedoic Acid/Ezetimibe16$15,113
Praluent PenAlirocumab23$15,062
Rosuvastatin Calcium611$14,269
Ezetimibe454$13,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$938$684,283559 claims
Johnson & JohnsonXarelto$719$364,892313 claims
NovartisEntresto$894$271,709203 claims
AstraZenecaFarxiga, Brilinta$1,331$159,833147 claims
E.r. Squibb & Sons, L.L.C.Camzyos$711$111,17214 claims
Boehringer IngelheimJardiance$450$95,77084 claims
MerckVerquvo$1,007$34,05828 claims
Sanofi-aventis U.S. LLCMultaq$81$23,46014 claims
Esperion Therapeutics, Inc.Nexlizet$299$15,11316 claims
Novo NordiskOzempic$596$11,41114 claims
Lilly USA, LLCTrulicity$30$10,02711 claims
AmgenCorlanor$1,406$6,19712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →